Further, dual inhibition of p110γ and p110δ has been shown to abrogate murine CD8+ activity ex-vivo [19], while in-vivo demonstrated limited effect on poorly immunogenic HNSCC in a mouse model, even in conjunction with PD-L1 blockade [26]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.